PHASE 3 STUDY:LOW GRADE LYMPH COMP CYCLOPHOSPHAMIDE/FLUDARABINE TO STD THER FOL

第 3 阶段研究：低级别淋巴组合物环磷酰胺/氟达拉滨至 STD THER FOL

• 批准号: 7378554
• 负责人: CHRISTOPHER EHMANN
• 金额: $ 0.39万
• 依托单位: PENNSYLVANIA STATE UNIV HERSHEY MED CTR
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378554
• 关键词: PHASE; STUDY; LOW; GRADE; LYMPH

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to compare the response rate, time to progression and survival for patients with low-grade lymphoma treated with the Cyclophosphamide/Fludarabine regimen with a control arm of standard CVP. The study will also determine the effect of maintenance with anti-CD20 on time to progression and survival and its effect on lymphocytic number, subsets and quantitative immunoglobin levels over time.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。本研究的目的是比较环磷酰胺/氟达拉滨方案与标准CVP对照组治疗的低度恶性淋巴瘤患者的缓解率、至进展时间和生存期。本研究还将确定抗CD 20维持治疗对至进展时间和生存期的影响，以及随时间推移对淋巴细胞数量、亚群和定量免疫球蛋白水平的影响。